Minimisation of aminoglycoside toxicity in patients with cystic fibrosis - Wikidata - awgldk - TriplyDB

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

http://www.wikidata.org/entity/Q33775991

about

Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis Interventions for the eradication of methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis Occurrence and risk of cochleotoxicity in cystic fibrosis patients receiving repeated high-dose aminoglycoside therapy.Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.Eradication therapy for Burkholderia cepacia complex in people with cystic fibrosis.Changes in the inner ear structures in cystic fibrosis patients.Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.The future of aged care.Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions.

P2860

Q22306318-595A9A06-53A7-461C-B466-90F81EF1A5EF Q24186014-FC61FBD7-9EF5-4E63-A6D0-158A86831E54 Q24187987-6A613D23-894D-44BA-80A3-A33714F254BE Q24188313-032193AE-AC27-4D85-A22C-48232D82FCD6 Q24193082-8B4097AF-13C2-4F7A-8D70-F7D5C48342FF Q24200604-F2C1FE52-432E-400F-80C4-1E8A9EBFD24A Q24200822-759E740F-B222-4D98-8AFB-DBF07C2C8693 Q24203710-1334D824-30CE-43EA-B0CA-06094506241E Q24241057-0F42492D-228D-47B1-AABF-A71CC1752A4F Q33982886-E8320ED3-E2D3-4827-9DDB-B4CDCAF979C0 Q38133781-FE25CB9D-9EDA-42EC-9182-6F53F24B2BC4 Q38871831-D8492445-1592-475C-87E0-3E3477448349 Q38996423-0D1A6CFA-1B85-49B6-98BA-8C3BD86B13FC Q39066887-1BC3E520-07F1-4CDD-AEC5-B739685084BE Q39557669-BF624D98-93BB-4AFE-8122-DE918A929BC3 Q40594948-E7BA63A1-E435-4B59-9290-331E6B53C4C8 Q45019997-E410B28D-F539-4979-B4E7-1B509887B829 Q50435277-C96F383E-3322-4427-A301-221750FA12BB

P2860

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

http://www.wikidata.org/entity/Q33775991

description

1996 nî lūn-bûn

@nan

1996 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1996 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

name

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@ast

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@en

type

label

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@ast

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@en

prefLabel

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@ast

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@en

P1433

Q33775991-C5BBB6FB-FF21-4468-91E2-81DCBD399722

P1476

Q33775991-ADB63977-7239-4A3F-8B5F-030ACB2D58BF

P2093

Q33775991-08ED13CE-E59B-432A-8287-F78519FC5516

Q33775991-14DD7DF4-A9E2-4CFF-90DE-83991340E176

Q33775991-1C26E113-1C82-4D46-8059-3544A218E000

Q33775991-21096771-2D5D-4F07-94CB-48995E7F3060

Q33775991-4AF7C4B0-2F6A-4EE0-AA89-36DD1B70C256

Q33775991-4CC4B00D-A9F0-4AF0-B0E4-3425A846D692

Q33775991-629F2503-9FCB-413C-86CA-C70FAF4443BF

Q33775991-F8F4BC21-DC31-456D-9C1F-2479B916C59B

P2860

Q33775991-02219950-A5D5-4342-9491-BAC476A5EDF5

Q33775991-087D8794-4A4F-4960-89D2-C56F467449C9

Q33775991-1C7BC543-AB68-4676-A1DA-B437BB76FA09

Q33775991-1E2B9492-F3F0-461D-A029-54211D1E00E8

Q33775991-2E3CE3C4-0248-4B33-8E61-DB84C334A0B0

Q33775991-36136630-8A5E-4960-86B0-05F4C1047963

Q33775991-39DA1ADE-8603-435E-B2F6-ABC74E70D8E0

Q33775991-496F05D3-E270-4C7D-896D-F9E12FEDA17E

Q33775991-53E1DCA6-DCDE-4717-B601-29CD4C6DE6B8

Q33775991-60746EB2-A53B-4B16-8890-33E341672A9A

P304

Q33775991-31B0525A-9835-4792-8CA0-5703E3AC946A

P31

Q33775991-57A6EE35-14DE-4EE1-949E-FE5E6AA8DDC6

P356

Q33775991-C67EECEC-2EC6-4AA1-BC5B-58C81CD797DD

P407

Q33775991-3F6054D9-3B54-4D88-990D-1E0C5FE2BB4F

P433

Q33775991-01AB39CF-1A6E-43AA-9AD4-49BC3A9018FD

P478

Q33775991-ABD3FCD3-58A9-4545-A31E-5EB7E6D208D3

P577

Q33775991-5DF063CC-DA1F-4AF8-9957-166D38BC78CD

P5875

Q33775991-648E3A37-6B0C-45BA-A8BD-1B02F7284654

P698

Q33775991-6A069115-8E3A-4C24-BD8A-D67E011DF6D1

P921

Q33775991-596D0A71-40AE-44D0-B211-1263B3AFE4C4

P932

Q33775991-6C99EA79-D6EC-4D1D-AC03-FAE32A38416F

P356

P1433

P1476

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

@en

P2093

Hickey B

http://www.w3.org/2001/XMLSchema#string

Hooper RE

http://www.w3.org/2001/XMLSchema#string

Ioannides-Demos LL

http://www.w3.org/2001/XMLSchema#string

Li SC

http://www.w3.org/2001/XMLSchema#string

McLean AJ

http://www.w3.org/2001/XMLSchema#string

Spicer WJ

http://www.w3.org/2001/XMLSchema#string

Williams TJ

http://www.w3.org/2001/XMLSchema#string

Wood PJ

http://www.w3.org/2001/XMLSchema#string

P2860

Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients

Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin

Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis

Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs.

Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects.

Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.

Microbiology of lung infection in cystic fibrosis.

Aminoglycoside binding sites in the inner ears of guinea pigs.

Cystic fibrosis: respiratory problems and their treatment.

A critical reevaluation of the "therapeutic range" of aminoglycosides.

P304

369-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.51.4.369

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

1996-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14468001

http://www.w3.org/2001/XMLSchema#string

P698

8733487

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

1090670

http://www.w3.org/2001/XMLSchema#string